Tags : CRISPR Therapeutics

CRISPR Therapeutics and Vertex Report Results of CTX001 from First

Shots: The two P-I/ II studies, CLIMB-Thal-111 & CLIMB-SCD-121 studies will assess CTX001 in patients with transfusion-dependent beta-thalassemia & sickle cell disease aged 18-35yrs. and enrolls up to 45 patients with a follow up of ~2yrs. after infusion at six clinical sites       respectively The studies demonstrated a total hemoglobin level of 11.9 g/dL & […]Read More

PharmaShots Weekly Snapshot (October 14-18, 2019)

1. Johnson & Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US Published: Oct 18, 2019 | Tags: JnJ, Initiates, Voluntarily, Recall, Baby Powder, US 2. AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis Published: Oct 18, 2019 | Tags: AbbVie, Rinvoq, Upadacitinib, Receives, […]Read More

CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights

Shots: CRISPR to gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs while KSQ will get access to CRISPR’ IP for its autologous cell therapies including its existing eTIL cell franchise The agreement allows KSQ to leverage CRISPR’s editing technology in its eTIL programs, […]Read More

Vertex to Expand its Collaboration with CRISPR Therapeutics to Develop

Shots: Vertex signs a licensing agreement with CRISPR to develop & discover gene editing therapies for DMD and DM1. CRISPR to get $1B, as total deal value including $175M upfront, milestones and royalties on sales. Vertex to get exclusive WW rights for IPR of gene editing therapies including foundational CRISPR/Cas9 technology, novel endonucleases, single and […]Read More

ProBioGen and CRISPR Therapeutics Signs a Multi-Year Research Collaboration for

Shots: The companies collaborated to develop and commercialize novel in vivo delivery of CRISPR/Cas9 using ProBioGen’s technology. CRISPR Therapeutics also holds an option to license the developed product The focus of the agreement is to expand CRISPR Therapeutics’ in vivo delivery technology in fields of hemoglobinopathies, oncology, regenerative medicine and rare diseases CRISPR Therapeutics’ CRISPR/Cas9 […]Read More